<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887483</url>
  </required_header>
  <id_info>
    <org_study_id>KF_2013</org_study_id>
    <nct_id>NCT01887483</nct_id>
  </id_info>
  <brief_title>Vetal Laban Intervention Trial Assessing Bowel Symptoms</brief_title>
  <acronym>KF_2013</acronym>
  <official_title>A Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 Month Consumption of Vetal Laban Including L. Acidophilus on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for IBS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Almarai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinart International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two month intervention trial assessing the effect of Vetal Laban containing L. acidophilus
      on enhancing functional bowel wellbeing among subjects with irritable bowel syndrome (IBS).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment, high drop-out
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in functional bowel symptoms</measure>
    <time_frame>week 0, 4, 8, 12 and 16</time_frame>
    <description>Validated questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in adequate relief of bowel symptoms</measure>
    <time_frame>weekly from week 4 to week 12</time_frame>
    <description>Weekly question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in stool defecation frequency</measure>
    <time_frame>week 0, 4, 8, 12 and 16</time_frame>
    <description>Validated scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in stool microbiota</measure>
    <time_frame>week 4, 8, 12 and 16</time_frame>
    <description>molecular analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in prevalence of adverse events</measure>
    <time_frame>continuous from week 0 to 16</time_frame>
    <description>Recording of adverse and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in stool consistency</measure>
    <time_frame>week 0, 4, 8, 12 and 16</time_frame>
    <description>Validated scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Vetal Laban active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vetal Laban with L. acidophilus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vetal Laban -like product without L. acidophilus</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vetal Laban active</intervention_name>
    <description>Dairy product with probiotic</description>
    <arm_group_label>Vetal Laban active</arm_group_label>
    <other_name>Vetal Laban, Lactobacillus acidophilus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dairy product without probiotic</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vetal Laban-like product without L. acidophilus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18 to 65 years

          -  Subjects fulfilling Rome III criteria for IBS

          -  Sufficient health and orientation for participating in the trial

          -  Obtained his/her informed consent after verbal and written information.

          -  Have a high probability for compliance with and completion of the study.

          -  Body Mass Index (BMI) between 19 and 35.

        Exclusion Criteria:

          -  Diagnosed or suspected organic gastrointestinal disease (i.e. colitis, Crohn's
             disease, celiac disease, major bowel surgery, recurrent diverticulitis) or severely
             impaired general health including cancer and cancer therapy.

          -  Lactose intolerance

          -  Unwillingness to refrain from probiotic use during the trial

          -  Use of antibiotics within the 3 preceding months prior to recruitment

          -  Pregnant, planning pregnancy or lactating

          -  Expected major lifestyle changes related to nutrition, exercise, travelling etc.

          -  Participation in a clinical trial with an investigational product or drug within 3
             months prior to screening.

          -  Substance abuse

          -  Subjects unable to read and understand the questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullah Aljahdali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Abdulaziz National Guard Hospital, Riyadh, Kingdom of Saudi Arabia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur C Ouwehand, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Danisco Sweeteners Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna H Lyra, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Danisco Sweeteners Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzanne Alodaib, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Almarai Company, Saudi Arabia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abed Allehibi, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Fahd Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Othman Al-Harbi, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Khalid University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Fahd Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Khalid University Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>bowel function</keyword>
  <keyword>probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

